Inadequate clinical trial representations of all ... the access to and quality of healthcare, and concerns of trial under-representation are likely to influence trust issues, of which the latter ...
The World Health Organization wants to tackle inequity and bureaucracy relating to clinical trials. Will its latest guidance make a difference? Anna Volkmer reports During the covid-19 pandemic the UK ...
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss which populations are seen as the most underrepresented in oncology clinical trials.
Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different genders, races, ages and life histories, chances ...
The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or ...
Hosted on MSN13d
EU’s Clinical Trials Regulation comes into full forceThe ruling requires all trials across the EU to be filed through the European Medicines Agency’s digital filing system.
It was due to be finalized by June 2025. "Poor representation in clinical trials reduces our understanding of drug responses and safety for all groups," said Jeanne Regnante, a health equity life ...
The study revealed a lack of equitable representation in trials of head and neck cancer. Oncologists can help by ensuring that all their patients are screened for clinical trial eligibility.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback